1 asset in Hyper-IgE Syndrome

Therapeutic assets addressing Hyper-IgE Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
cd3/cd19 negative allogeneic hematopoietic stem cells Hyper-IgE Syndrome	Paul Szabolcs	P1/2	CCC (48)